{
  "title": "Staging Systems: Alternative Staging Systems (Ann Arbor, FIGO, etc.)",
  "category": "Clinical Assessment",
  "section": "Cancer Staging",
  "summary": "Comprehensive guide to non-TNM staging systems used in hematologic, gynecologic, and pediatric malignancies.",
  "author": "OncoVISTA Team",
  "lastUpdated": "2023-10-20T00:00:00Z",
  "version": "1.1.0",
  "metadata": {
    "reviewStatus": "peer-reviewed",
    "readingTimeMinutes": 15,
    "targetAudience": ["Oncologists", "Hematologists", "Gynecologists", "Pediatric Oncologists"]
  },
  "content": [
    {
      "type": "heading",
      "level": 1,
      "text": "Staging Systems"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Topic 5: Alternative Staging Systems (Ann Arbor, FIGO, etc.)"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "1. Introduction"
    },
    {
      "type": "paragraph",
      "text": "Several malignanciesâ€”especially in hematology, gynecology, and pediatricsâ€”require non-TNM staging systems due to distinct spread patterns and treatment strategies. These include:"
    },
    {
      "type": "list",
      "items": [
        "Ann Arbor/Lugano (Lymphoma)",
        "FIGO (Gynecologic cancers)",
        "Durie-Salmon / ISS / R-ISS (Multiple myeloma)",
        "INRG / INSS (Pediatric neuroblastoma)"
      ]
    },
    {
      "type": "heading",
      "level": 3,
      "text": "2. Ann Arbor and Lugano â€“ Lymphoma"
    },
    {
      "type": "paragraph",
      "text": "Used for Hodgkin and most non-Hodgkin lymphomas:"
    },
    {
      "type": "table",
      "headers": ["Stage", "Description"],
      "rows": [
        ["I", "Single nodal region or single extranodal site (IE)"],
        ["II", "â‰¥2 regions on same side of diaphragm"],
        ["III", "Nodes on both sides of diaphragm"],
        ["IV", "Diffuse/disseminated extranodal involvement (e.g., marrow, liver)"]
      ]
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Modifiers:"
    },
    {
      "type": "list",
      "items": [
        "A/B: Absence/presence of systemic symptoms",
        "E: Contiguous extranodal spread",
        "X: Bulky disease (e.g., mediastinal mass â‰¥1/3 thoracic diameter)"
      ]
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Lugano Classification (2014):"
    },
    {
      "type": "list",
      "items": [
        "Recommends PET/CT for staging HL and aggressive NHL",
        "Introduces Deauville score for response"
      ]
    },
    {
      "type": "paragraph",
      "text": "See full details here: ðŸ”— [Non-Hodgkin Lymphomas](https://www.amboss.com/us/knowledge/non-hodgkin-lymphomas)"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "3. FIGO Staging â€“ Gynecologic Cancers"
    },
    {
      "type": "heading",
      "level": 4,
      "text": "A. Cervical Cancer (FIGO 2018)"
    },
    {
      "type": "table",
      "headers": ["Stage", "Description"],
      "rows": [
        ["I", "Confined to cervix"],
        ["â€¢ IA: Microscopic invasion â‰¤5 mm", ""],
        ["â€¢ IB: Invasion >5 mm (IB1: â‰¤2 cm, IB2: 2â€“4 cm, IB3: >4 cm)", ""],
        ["II", "Beyond uterus, not into pelvic wall"],
        ["â€¢ IIA: Upper 2/3 vagina, no parametrial invasion", ""],
        ["â€¢ IIB: Parametrial invasion", ""],
        ["III", "Extends to pelvic wall, lower vagina, hydronephrosis, or nodal spread"],
        ["â€¢ IIIA: Lower 1/3 vagina", ""],
        ["â€¢ IIIB: Pelvic wall or hydronephrosis", ""],
        ["â€¢ IIIC: Pelvic (IIIC1) or paraaortic (IIIC2) lymph nodes", ""],
        ["IV", "Adjacent organ or distant metastases"],
        ["â€¢ IVA: Bladder/rectal mucosa", ""],
        ["â€¢ IVB: Distant organs", ""]
      ]
    },
    {
      "type": "paragraph",
      "text": "See: ðŸ”— [Invasive Cervical Cancer](https://www.amboss.com/us/knowledge/invasive-cervical-cancer)"
    },
    {
      "type": "heading",
      "level": 4,
      "text": "B. Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (FIGO)"
    },
    {
      "type": "table",
      "headers": ["Stage", "Description"],
      "rows": [
        ["I", "Limited to ovaries/fallopian tubes"],
        ["â€¢ IAâ€“IB: One/both ovaries, capsule intact", ""],
        ["â€¢ IC1â€“3: Surgical spill, capsule rupture, or positive peritoneal cytology", ""],
        ["II", "Pelvic extension"],
        ["â€¢ IIA: Uterus or tubes", ""],
        ["â€¢ IIB: Pelvic peritoneum", ""],
        ["III", "Peritoneal spread outside pelvis or retroperitoneal nodes"],
        ["â€¢ IIIA1(i/ii): LN â‰¤10 mm or >10 mm", ""],
        ["â€¢ IIIA2: Microscopic spread to upper abdomen", ""],
        ["â€¢ IIIB: Macroscopic â‰¤2 cm", ""],
        ["â€¢ IIIC: Macroscopic >2 cm Â± liver/spleen surface", ""],
        ["IV", "Distant metastasis"],
        ["â€¢ IVA: Pleural effusion (positive cytology)", ""],
        ["â€¢ IVB: Liver parenchyma, distant nodes, extra-abdominal sites", ""]
      ]
    },
    {
      "type": "paragraph",
      "text": "See: ðŸ”— [Ovarian Cancer Staging](https://www.amboss.com/us/knowledge/ovarian-cancer)"
    },
    {
      "type": "heading",
      "level": 4,
      "text": "C. Endometrial Cancer (FIGO 2023)"
    },
    {
      "type": "table",
      "headers": ["Stage", "Description"],
      "rows": [
        ["I", "Uterus/ovary only"],
        ["â€¢ IA: Endometrium or superficial myometrium", ""],
        ["â€¢ IB: â‰¥50% myometrial invasion", ""],
        ["â€¢ IC: Aggressive histology confined to endometrium", ""],
        ["II", "Cervical involvement"],
        ["â€¢ IIA: Cervical stroma", ""],
        ["â€¢ IIB: Lymphovascular invasion", ""],
        ["â€¢ IIC: Aggressive histology with myometrial invasion", ""],
        ["III", "Local spread"],
        ["â€¢ IIIA: Serosa/adnexa", ""],
        ["â€¢ IIIB: Vagina/parametria", ""],
        ["â€¢ IIIC: Pelvic (IIIC1) or paraaortic (IIIC2) nodes", ""],
        ["IV", "Invasion/distant spread"],
        ["â€¢ IVA: Bladder/bowel", ""],
        ["â€¢ IVB: Extra-pelvic peritoneum", ""],
        ["â€¢ IVC: Distant metastases (e.g., lung)", ""]
      ]
    },
    {
      "type": "paragraph",
      "text": "See: ðŸ”— [Endometrial Cancer](https://www.amboss.com/us/knowledge/endometrial-cancer)"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "4. Durie-Salmon and R-ISS â€“ Multiple Myeloma"
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Durie-Salmon (Historic)"
    },
    {
      "type": "table",
      "headers": ["Stage", "Description"],
      "rows": [
        ["I", "Normal calcium, Hgb, no bone lesions, low M-protein"],
        ["II", "Intermediate"],
        ["III", "High tumor burden: anemia, hypercalcemia, â‰¥3 bone lesions"]
      ]
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Renal function subclass:"
    },
    {
      "type": "list",
      "items": [
        "A (Cr <2 mg/dL)",
        "B (Cr â‰¥2 mg/dL)"
      ]
    },
    {
      "type": "heading",
      "level": 4,
      "text": "R-ISS (Revised International Staging)"
    },
    {
      "type": "table",
      "headers": ["Stage", "Components"],
      "rows": [
        ["I", "ISS stage I + normal LDH + no high-risk cytogenetics"],
        ["II", "Not stage I or III"],
        ["III", "ISS III + elevated LDH or high-risk cytogenetics (e.g., del(17p), t(4;14))"]
      ]
    },
    {
      "type": "paragraph",
      "text": "See: ðŸ”— [Multiple Myeloma](https://www.amboss.com/us/knowledge/multiple-myeloma)"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "5. INRG â€“ Neuroblastoma"
    },
    {
      "type": "table",
      "headers": ["Stage", "Description"],
      "rows": [
        ["L1", "Localized tumor without image-defined risk factors (IDRFs)"],
        ["L2", "Localized tumor with IDRFs"],
        ["M", "Metastatic disease (excluding MS)"],
        ["MS", "Metastatic in infants (<18 months), skin/liver/marrow only"]
      ]
    },
    {
      "type": "clinical_pearl",
      "text": "Risk also determined by MYCN amplification, age, histology, and chromosome 1p/11q loss"
    },
    {
      "type": "paragraph",
      "text": "See: ðŸ”— [Neuroblastoma](https://www.amboss.com/us/knowledge/neuroblastoma)"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "6. Other Specialized Systems"
    },
    {
      "type": "table",
      "headers": ["Tumor", "System", "Highlights"],
      "rows": [
        ["Retinoblastoma", "International Classification", "Globe salvage potential"],
        ["Testicular cancer", "IGCCCG", "Combines TNM + serum markers (AFP, Î²-hCG, LDH)"],
        ["GIST", "NIH/Miettinen", "Based on size, mitotic index, site"],
        ["Sarcoma", "FNCLCC + AJCC", "Histologic grade and tumor depth drive risk"]
      ]
    },
    {
      "type": "heading",
      "level": 3,
      "text": "7. Summary"
    },
    {
      "type": "paragraph",
      "text": "Alternative staging systems provide crucial, site-specific insight where TNM is not applicable. Their use is fundamental in the care of hematologic, gynecologic, and pediatric malignancies. Familiarity with FIGO, Ann Arbor/Lugano, R-ISS, and INRG classifications ensures accurate prognosis, treatment selection, and trial eligibility."
    }
  ]
}